Additionally, in a nude mouse xenograft model, ABF treatment at high doses achieved tumor inhibition rates of 46.59% and 45.71%, respectively,and the expression of the tumor proliferation marker KI67 was significantly reduced.<h4>Conclusion</h4>ABF demonstrates promising anti-NPC potential, providing scientific evidence for the traditional anti-cancer use of SDG. Here, MKI67 is linked to nasopharyngeal carcinoma.